Blog

Blog - Most recent

Janssen Acquires XO1 Limited

Description

<p>Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. The opportunity was identified and facilitated through Johnson &amp; Johnson Innovation, London.</p>

Front teaser image

Johnson & Johnson Innovation – JJDC Makes $15 Million Investment in Vivo Capital Fund

Description

<p>SINGAPORE, 2 April, 2015 – Johnson &amp; Johnson Innovation – JJDC, Inc. (JJDC) today announced a USD $15 million commitment to Vivo Capital Fund VIII (“Vivo VIII”).&nbsp; Vivo Capital is an investment firm focused on investing in and developing healthcare companies in the U.S. and China.<br />
<br />
This investment in Vivo VIII provides late stage venture and early stage growth capital to be invested in the United States and China. This investment helps bridge two of the world’s largest healthcare markets and enables cross-country relationships that will allow for market expansion and access to new products. The fund aims to combine the innovation and expertise with the growth and capital of the different regions using their presence in both regions.</p>

Front teaser image

Johnson & Johnson Innovation Announces Collaboration on Immuno-Oncology Antibody ADC-1013 with Alligator Bioscience

Description

<p>HORSHAM, PA (August 12, 2015) – Janssen Biotech, Inc. (Janssen), one of the Janssen pharmaceutical companies of Johnson &amp; Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies. The agreement was facilitated by Johnson &amp; Johnson Innovation, London.</p>

Front teaser image

Johnson & Johnson Innovation Announces Collaborations with Canadian Biotechs Novera Therapeutics, Inc. and enGene, Inc.

Description

<p>BOSTON, MASSACHUSETTS (October 14, 2015) – Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, today announced collaborations with two Canadian biotechnology companies, Toronto-based Novera Therapeutics, Inc. and Montreal-based enGene, Inc. The agreements, facilitated by Johnson &amp; Johnson Innovation, seek to advance novel therapeutics for the treatment of hematological malignancies and inflammatory bowel disease (IBD).</p>

Front teaser image

Johnson & Johnson Innovation Announces Seventeen Collaborations with Focus on Advancing Global Healthcare through Transformational Science and Technologies

Description

<p>NEW BRUNSWICK (June 11, 2015) – Johnson &amp; Johnson Innovation today announced seventeen new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johnson &amp; Johnson Innovation to more than 200. Today’s announcement includes the first alliance for the Disease Interception Accelerator (DIA), a research agreement with Washington University to identify the root cause of type 1 diabetes and enable the development of interventions that halt progression to disease.</p>

Front teaser image

Ontario Government, University of Toronto, and MaRS secure Johnson & Johnson Innovation, JLABS for Toronto – first JLABS Incubator outside of United States

Description

<p><strong>TORONTO (SEPTEMBER 8, 2015)</strong></p>

<p>The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson &amp; Johnson Innovation, JLABS incubator model in Toronto. The new facility, called JLABS @ Toronto, will open in spring of 2016 at MaRS Discovery District and will support start-ups with lab space, programs, and potential investment partners as they work to build important, successful early-stage companies.</p>

Front teaser image

LifeScan Announces Strategic Collaboration with WellDoc Corporation to Advance Mobile Care Solutions for Type 2 Diabetes Patients

Description

<p><strong>BOSTON, MA. (March 1, 2016)</strong></p>

<p>LifeScan, Inc., a business within the Johnson &amp; Johnson Diabetes Care Companies and a world leader in blood glucose monitoring, today announced a strategic collaboration through its affiliate Cilag GmbH International with WellDoc Corporation (WellDoc) to advance mobile solutions that can empower Type 2 diabetes patients with real time data and information to improve their health outcomes. In addition, Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC) participated with other investors in WellDoc’s Series B financing. This new relationship exemplifies Johnson &amp; Johnson’s cross-sector strategy of collaborating with a wide range of technology companies to create new ways that help people live longer, healthier lives.</p>

Front teaser image

Johnson & Johnson Innovation Unveils JLABS @ TMC to Help Catalyze Early Stage Research through to Commercialization for Healthcare Solutions in Houston

Description

<p>HOUSTON, March 2, 2016 — Johnson &amp; Johnson Innovation LLC today opened JLABS @ TMC, a new 34,000-square foot life sciences incubator providing entrepreneurs shared lab space, private offices, and modular laboratory suites, as well as state of the art equipment and value-added operational, education, and business services. HOUSTON, March 2, 2016 — Johnson &amp; Johnson Innovation LLC today opened JLABS @ TMC, a new 34,000-square foot life sciences incubator providing entrepreneurs shared lab space, private offices, and modular laboratory suites, as well as state of the art equipment and value-added operational, education, and business services.&nbsp;</p>

Front teaser image

Johnson & Johnson Innovation Announces New Collaboration with TMC

Description

<p><strong>HOUSTON, October 18, 2016</strong></p>

<p><em>Medical Device Entrepreneur Billy Cohn, M.D. to Lead Johnson &amp; Johnson Innovation’s new Center for Device Innovation&nbsp;</em></p>

<p>&nbsp;Johnson &amp; Johnson Innovation LLC (JJI) today announced the creation of the Center for Device Innovation at Texas Medical Center (CDI @ TMC), a broad, new collaboration between JJI and TMC that aims to accelerate end-to-end development of breakthrough medical devices. This expands on JJI’s collaboration with TMC established earlier this year with the opening of JLABS @ TMC, combining the resources of the world’s largest medical complex with the capabilities of the Johnson &amp; Johnson Medical Devices Companies*, to advance the health and well-being of people around the globe.&nbsp;</p>

Front teaser image

Johnson & Johnson Innovation and Janssen Award U.S. $1.5 Million in Grants for World Without Disease QuickFire Challenge

Description

<p><strong>RMIT, Glyscend and Neurotrack each receive U.S. $500,000 research grant and offered residency at Johnson &amp; Johnson Innovation | JLABS.</strong></p>

<p>NEW YORK, Nov. 14, 2016 — Johnson &amp; Johnson Innovation LLC and Janssen Research &amp; Development, LLC (Janssen) today announced multiple recipients of U.S. $500,000 grants and offers of residency at Johnson &amp; Johnson Innovation | JLABS (JLABS) in the World Without Disease QuickFire Challenge. The announcement was made at the 2016 Partnering for Cures conference. The competition was the largest and most ambitious Johnson &amp; Johnson Innovation QuickFire Challenge to date, representing an ongoing commitment to support diverse life science innovations and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases.</p>

<p>Download the PDF for the full press release.</p>

Front teaser image